Silexion Reports AST RNAi drug leverages lipoproteins for systemic delivery
Silexion reported that its SIL204 utilizes native serum lipoproteins for cellular delivery, validating a mechanism for systemic administration in KRAS-driven cancers without artificial nanoparticles.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed